
Press Release

February 26, 2026

Sumitomo Pharma Co., Ltd.

Termination of License Agreement for Selective Orexin 2 Receptor Agonist DSP-0187

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; the “Company”) today announced that the Company will terminate the exclusive license agreement (the “Agreement”) executed in April 2022 with Jazz Pharmaceuticals plc (“Jazz”). Under the Agreement, the Company had granted Jazz exclusive rights to develop and commercialize DSP-0187 in territories worldwide, except for Japan, China, and certain other Asia-Pacific markets.

The termination of the Agreement results from Jazz’s decision to conclude the Agreement based on its own business strategy. Following the termination, the rights related to DSP-0187 in the relevant territories will revert to the Company. The Company will therefore hold global development rights for DSP-0187 and is currently evaluating the optimal development strategy. The impact of this matter on the Company’s consolidated financial results for the fiscal year ending March 2026 is expected to be minimal.

(Reference)

DSP-0187

DSP-0187 is an orexin 2 receptor agonist. It is expected to improve excessive daytime sleepiness (EDS) and cataplexy of narcolepsy caused by orexin deficiency. DSP-0187 is also expected to demonstrate efficacy in EDS conditions other than narcolepsy.

Contact:

Corporate Communications, Corporate Governance

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp